About the Transaction
Galbraith Laboratories, Inc. (“Galbraith”) (www.galbraith.com) is a premier analytical testing laboratory, offering expert healthcare analytical testing solutions to customers throughout the United States. In addition to healthcare testing, the Company also serves the Chemical, Cosmetics, Consumer, Manufacturing, and Environmental industries. Founded in 1950 and headquartered in Knoxville, TN, the Company has earned a strong reputation for solving its clients’ diverse analytical challenges through custom-developed methods and industry-specific knowledge.
Bureau Veritas SA (ENXTPA:BVI) (“BV”) (www.bureauveritas.com) is a world leader in laboratory testing, inspection, and certification services. Founded in 1828, Bureau Veritas’ 80,000 employees serve a variety of industries including: Automotive, Transport & Aerospace, Buildings & Infrastructure, Commodities, Consumer Products & Retail, Cybersecurity, Agri-food, Oil & Gas, and Power & Utilities, among others. Serving its 400,000+ customers from over 1,600 offices worldwide, Bureau Veritas helps its clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Didier Michaud-Daniel, Chief Executive Officer of Bureau Veritas, commented on the acquisition:
Bureau Veritas is delighted to welcome the Galbraith team. By joining forces, we will strengthen our presence in North America, a key hub for the expansion of our Consumer Products Services activities. Building on its strong market recognition by global brands and manufacturers, Galbraith’s expertise will help expand our analytical capabilities in the Consumer Healthcare, Personal Care & Industrial Chemical markets.
Brenda Thornburgh, Owner of Galbraith, added:
By joining Bureau Veritas, we look forward to expanding our capabilities and client services by leveraging the Group’s extensive geographic footprint and global leadership. We are proud of our advanced analytical capabilities, which we now share with Bureau Veritas worldwide. Through our combined expertise, we will be able to offer unique analytical testing services solutions to our clients.
The acquisition of Galbraith expands Bureau Veritas’ position in the Consumer Healthcare, Personal Care, and Industrial Chemical markets in the United States. This is the second acquisition in the United States that Bureau Veritas has completed in 2022, for which Paramax has served as the exclusive buyside M&A advisor.
